Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of
cardiovascular morbidity and mortality. An ability to identify patients with HFpEF who are at …

Aims Heart failure (HF) with normal or preserved left ventricular (LV) ejection fraction
(HFPEF) has been reported to be associated with similar outcome as HF with reduced EF …

Background It has been reported that recovery of left ventricular ejection fraction (LVEF) is
associated with better prognosis in heart failure (HF) patients with reduced EF (rEF) …

Background Although potential therapeutic candidates for heart failure with preserved
ejection fraction (HFpEF) are emerging, it is still unclear whether they will be effective in …

The relative impact of comorbidities and parameters of left ventricular diastolic function on
clinical outcome has not been thoroughly investigated in patients who are hospitalized for …

Aims The prognostic impact of coronary artery disease (CAD) in heart failure is debated.
Whereas causes of death have been well described in patients with cardiomyopathy, little is …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome associated
with poor quality of life, substantial health-care resource utilization, and premature mortality …

Aims A substantial proportion of patients with heart failure have preserved left ventricular
ejection fraction (HF-PEF). Previous studies have reported mixed results whether survival is …

Heart failure with preserved ejection fraction (HFpEF) has a high clinical burden and
constitutes approximately 20% to 30% of patients with heart failure in Asia. Impaired global …

Despite significant advances in therapies for patients with heart failure with reduced ejection
fraction (HFrEF), there are no evidence-based therapies for heart failure with preserved …